drugset / Trial / NCT05501821
Study of KBA1412 in Participants With Advanced Solid Malignant Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this trial is to assess the safety and efficacy of KBA1412, a patient derived, fully human, monoclonal antibody targeting CD9, in patients with advanced solid malignant tumors
Timeline
- Start
- 2022-08-08
- Primary completion
- 2024-07-24
- Completion
- 2024-07-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KBA1412 | Monoclonal antibody | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.